Jasper Therapeutics (JSPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $40.00 price target.
Emily Bodnar’s rating is based on the promising preliminary data from Jasper Therapeutics’ BEACON study, which evaluates briquilimab for the treatment of chronic spontaneous urticaria (CSU). The study showed that higher doses of the drug led to significant improvements in patient outcomes, with some doses achieving complete control of symptoms. Additionally, the reduction in tryptase levels and the durability of the response suggest that the treatment could be effective in the long term.
Furthermore, the ongoing SPOTLIGHT study supports these findings, demonstrating a high response rate in patients with cold urticaria and symptomatic dermagraphism. The addition of a new cohort in the SPOTLIGHT study could provide further insights into the efficacy and durability of different dosing regimens. These factors contribute to the anticipation of more comprehensive data in mid-2025, which could solidify the drug’s potential and support its progression to a Phase 2b trial, ultimately justifying the Buy rating.
In another report released on February 18, JMP Securities also reiterated a Buy rating on the stock with a $70.00 price target.